Stockholm - Delayed Quote SEK

Xvivo Perfusion AB (publ) (XVIVO.ST)

333.00
+8.40
+(2.59%)
At close: May 14 at 5:29:45 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Mr. Christoffer Rosenblad Chief Executive Officer 7.39M -- 1975
Mr. Kristoffer Nordstrom Chief Financial Officer -- -- 1985
Ms. Lena Hagman B.Sc. COO & Deputy CEO -- -- 1965
Ms. Ylva Vihoj Senior Vice President of Human Resources -- -- 1970
Dr. Magnus Nilsson Ph.D. Senior Advisor -- -- 1956
Mr. Andreas Wallinder M.D., Ph.D. Chief Medical Officer -- -- 1977
Mr. Johan Holmstrom Senior Vice President of Commercial Europe & RoW -- -- 1970
Ms. Jaya Tiwari Senior Vice President of Clinical & Regulatory Affairs North America -- -- 1987
Mr. Mark Reade Senior Vice President of North America -- -- 1963

Xvivo Perfusion AB (publ)

Gemenskapens gata 9
Mölndal, 431 53
Sweden
46 3 17 88 21 50 https://www.xvivogroup.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
193

Description

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Corporate Governance

Xvivo Perfusion AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

July 11, 2025 at 5:30 AM UTC

Xvivo Perfusion AB (publ) Earnings Date

Recent Events

Related Tickers